Trial
NCT04050293
Therapy for Migraine Prevention in Children 6-11 Years of Age
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Supernus Pharmaceuticals, Inc.
Collaborators
—
Condition
Migraine Disorders
Intervention
SPN-538
Why stopped
Difficulty in recruitment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-22